Search
Now showing items 1-1 of 1
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
Wissenschaftlicher Artikel
(Universität Ulm, 2005)